Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of …
M O'Brien, L Paz-Ares, S Marreaud, U Dafni… - The Lancet …, 2022 - thelancet.com
Background Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer
(NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage …
(NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage …
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
MA Socinski, RM Jotte, F Cappuzzo… - … England Journal of …, 2018 - Mass Medical Soc
Background The cancer-cell–killing property of atezolizumab may be enhanced by the
blockade of vascular endothelial growth factor–mediated immunosuppression with …
blockade of vascular endothelial growth factor–mediated immunosuppression with …
[PDF][PDF] Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative …
World Health Organization - 2018 - apps.who.int
In 2017, the Seventieth World Health Assembly adopted resolution WHA70. 12 on Cancer
prevention and control in the context of an integrated approach (Appendix A). Operative …
prevention and control in the context of an integrated approach (Appendix A). Operative …
[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III …
L Horn, DR Spigel, EE Vokes, E Holgado… - Journal of clinical …, 2017 - ascopubs.org
Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared
with docetaxel in two independent phase III studies in previously treated patients with …
with docetaxel in two independent phase III studies in previously treated patients with …
[HTML][HTML] Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino… - … England Journal of …, 2017 - Mass Medical Soc
Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …